{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:49:28Z","timestamp":1790916568764,"version":"4.1.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ad.2023.10.019","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T21:25:33Z","timestamp":1698787533000},"page":"T56-T65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["[Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases"],"prefix":"10.1016","volume":"115","author":[{"given":"E.","family":"Vilarrasa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Nicolau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"de la Cueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Goday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Martorell-Calatayud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Carrascosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2023.10.019_bib0440","doi-asserted-by":"crossref","first-page":"E691","DOI":"10.1152\/ajpendo.00297.2015","article-title":"Revisiting the adipocyte: a model for integration of cytokine signaling in the regulation of energy metabolism","volume":"309","author":"Rodr\u00edguez","year":"2015","journal-title":"Am J Physiol Endocrinol Metab."},{"key":"10.1016\/j.ad.2023.10.019_bib0445","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.immuni.2021.12.013","article-title":"Inflammation in obesity, diabetes, and related disorders","volume":"55","author":"Rohm","year":"2022","journal-title":"Immunity."},{"key":"10.1016\/j.ad.2023.10.019_bib0450","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.cmet.2013.02.009","article-title":"Class II major histocompatibility complex plays an essential role in obesity-induced adipose inflammation","volume":"17","author":"Deng","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.ad.2023.10.019_bib0455","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.3389\/fphys.2019.01607","article-title":"Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes","volume":"10","author":"Zatterale","year":"2020","journal-title":"Front Physiol."},{"key":"10.1016\/j.ad.2023.10.019_bib0460","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jaad.2018.12.070","article-title":"Skin changes in the obese patient","volume":"81","author":"Hirt","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2023.10.019_bib0465","doi-asserted-by":"crossref","first-page":"7499","DOI":"10.3390\/ijms23147499","article-title":"Exploring the Links between Obesity and Psoriasis: A Comprehensive Review","volume":"23","author":"Barros","year":"2022","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.ad.2023.10.019_bib0470","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ad.2012.08.003","article-title":"Obesity and psoriasis: inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications","volume":"105","author":"Carrascosa","year":"2014","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.ad.2023.10.019_bib0475","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.autrev.2014.07.001","article-title":"Obesity in autoimmune diseases: not a passive bystander","volume":"13","author":"Versini","year":"2014","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.ad.2023.10.019_bib0480","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/ijd.14864","article-title":"Global burden of psoriasis - comparison of regional and global epidemiology, 1990 to 2017","volume":"59","author":"AlQassimi","year":"2020","journal-title":"Int J Dermatol."},{"key":"10.1016\/j.ad.2023.10.019_bib0485","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1159\/000448515","article-title":"Hospitalisations with Hidradenitis Suppurativa: An Increasing Problem That Deserves Closer Attention","volume":"232","author":"Santos","year":"2016","journal-title":"Dermatology."},{"key":"10.1016\/j.ad.2023.10.019_bib0490","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.rdc.2015.07.008","article-title":"Comorbidities in psoriatic arthritis","volume":"41","author":"Husni","year":"2015","journal-title":"Rheum Dis Clin North Am."},{"key":"10.1016\/j.ad.2023.10.019_bib0495","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00296-016-3487-2","article-title":"Updates on cardiovascular comorbidities associated with psoriatic diseases: epidemiology and mechanisms","volume":"37","author":"Yim","year":"2017","journal-title":"Rheumatol Int."},{"key":"10.1016\/j.ad.2023.10.019_bib0500","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","article-title":"Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study","volume":"74","author":"Ogdie","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ad.2023.10.019_bib0505","first-page":"2167","article-title":"Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","volume":"33","author":"Han","year":"2006","journal-title":"J Rheumatol."},{"key":"10.1016\/j.ad.2023.10.019_bib0510","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1159\/000455840","article-title":"Psoriasis and obesity","volume":"232","author":"Jensen","year":"2016","journal-title":"Dermatology."},{"key":"10.1016\/j.ad.2023.10.019_bib0515","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000433528","article-title":"Prevalence of Obesity in Patients with Psoriasis: Results of the National Study PsoHealth3","volume":"231","author":"Jacobi","year":"2015","journal-title":"Dermatology."},{"key":"10.1016\/j.ad.2023.10.019_bib0520","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jaad.2006.08.040","article-title":"Prevalence of cardiovascular risk factors in patients with psoriasis","volume":"55","author":"Neimann","year":"2006","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2023.10.019_bib0525","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/0190-9622(95)91336-X","article-title":"Disease concomitance in psoriasis","volume":"32","author":"Henseler","year":"1995","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2023.10.019_bib0530","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/archinte.167.15.1670","article-title":"Obesity, Waist Circumference, Weight Change, and the Risk of Psoriasis in Women: Nurses\u2019 Health Study II","volume":"167","author":"Setty","year":"2007","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.ad.2023.10.019_bib0535","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.0022-202X.2005.23681.x","article-title":"Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study","volume":"125","author":"Naldi","year":"2005","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.ad.2023.10.019_bib0540","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.jaad.2021.06.012","article-title":"Risk of psoriasis according to body mass index: A retrospective cohort analysis","volume":"86","author":"Norden","year":"2022","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2023.10.019_bib0545","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1365-2133.2008.08655.x","article-title":"Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation","volume":"159","author":"Johnston","year":"2008","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2023.10.019_bib0550","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jdermsci.2009.02.009","article-title":"Serum high molecular weight adiponectin levels are decreased in psoriasis patients","volume":"55","author":"Shibata","year":"2009","journal-title":"J Dermatol Sci."},{"key":"10.1016\/j.ad.2023.10.019_bib0555","first-page":"667","article-title":"Adiponectin as an anti-inflammatory factor in the pathogenesis of psoriasis: induction of elevated serum adiponectin levels following therapy","volume":"164","author":"Shibata","year":"2011","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2023.10.019_bib0560","first-page":"1","article-title":"Type 2 diabetes and psoriasis: links and risks","volume":"9","author":"Holm","year":"2019","journal-title":"Psoriasis (Auckl)."},{"key":"10.1016\/j.ad.2023.10.019_bib0565","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1074\/jbc.M109.074252","article-title":"Adipocyte apoptosis, a link between obesity, insulin resistance, and hepatic steatosis","volume":"285","author":"Alkhouri","year":"2010","journal-title":"J Biol Chem."},{"key":"10.1016\/j.ad.2023.10.019_bib0570","doi-asserted-by":"crossref","first-page":"742713","DOI":"10.3389\/fmed.2021.742713","article-title":"Update on Cardiovascular Risk and Obesity in Psoriatic Arthritis","volume":"8","author":"Ram\u00edrez","year":"2021","journal-title":"Front Med (Lausanne)."},{"key":"10.1016\/j.ad.2023.10.019_bib0575","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J."},{"key":"10.1016\/j.ad.2023.10.019_bib0580","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000156599","article-title":"Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis","volume":"217","author":"Naldi","year":"2008","journal-title":"Dermatology."},{"issue":"Suppl 1","key":"10.1016\/j.ad.2023.10.019_bib0585","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1111\/j.1529-8019.2009.01281.x","article-title":"Correlation between BMI and PASI in patients affected by moderate to severe psoriasis undergoing biological therapy","volume":"23","author":"Bardazzi","year":"2010","journal-title":"Dermatol Ther."},{"key":"10.1016\/j.ad.2023.10.019_bib0590","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jaad.2021.01.059","article-title":"Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations","volume":"86","author":"Garg","year":"2022","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2023.10.019_bib0595","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/bjd.14024","article-title":"Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies","volume":"173","author":"Tzellos","year":"2015","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2023.10.019_bib0600","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/pde.12271","article-title":"Skin disorders associated with obesity in children and adolescents: a population-based study","volume":"31","author":"Mirmirani","year":"2014","journal-title":"Pediatr Dermatol."},{"key":"10.1016\/j.ad.2023.10.019_bib0605","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00011-020-01381-7","article-title":"Transcriptomic analysis of hidradenitis suppurativa skin suggests roles for multiple inflammatory pathways in disease pathogenesis","volume":"69","author":"Rumberger","year":"2020","journal-title":"Inflamm Res."},{"key":"10.1016\/j.ad.2023.10.019_bib0610","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1111\/ijd.16244","article-title":"Serum inflammatory markers and leukocyte profiles accurately describe hidradenitis suppurativa disease severity","volume":"61","author":"Andriano","year":"2022","journal-title":"Int J Dermatol."},{"key":"10.1016\/j.ad.2023.10.019_bib0615","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jid.2020.08.016","article-title":"Outcomes of Routine Diabetes Screening for Patients with Hidradenitis Suppurativa","volume":"141","author":"Ahmad","year":"2021","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.ad.2023.10.019_bib0620","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1001\/jamadermatol.2014.1165","article-title":"Association of Metabolic Syndrome and Hidradenitis Suppurativa","volume":"150","author":"Miller","year":"2014","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.ad.2023.10.019_bib0625","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jid.2018.01.009","article-title":"Hidradenitis suppurativa is associated with polycystic ovary syndrome: A population-based analysis in the United States","volume":"138","author":"Garg","year":"2018","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.ad.2023.10.019_bib0630","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ijwd.2019.06.026","article-title":"Comorbidities of hidradenitis suppurativa: A review of the literature","volume":"5","author":"Cartron","year":"2019","journal-title":"Int J Womens Dermatol."},{"key":"10.1016\/j.ad.2023.10.019_bib0635","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1001\/jamadermatol.2015.6264","article-title":"Risk of Major Adverse Cardiovascular Events and All-Cause Mortality in Patients With Hidradenitis Suppurativa","volume":"152","author":"Egeberg","year":"2016","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.ad.2023.10.019_bib0640","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/ijo.2015.64","article-title":"Effect of lifestyle weight loss intervention on disease severity in patients with psoriasis: a systematic review and meta-analysis","volume":"39","author":"Upala","year":"2015","journal-title":"Int J Obes (Lond)."},{"key":"10.1016\/j.ad.2023.10.019_bib0645","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1001\/jamadermatol.2013.722","article-title":"Effect of Weight Loss on the Severity of Psoriasis: A Randomized Clinical Study","volume":"149","author":"Jensen","year":"2013","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.ad.2023.10.019_bib0650","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/annrheumdis-2012-202812","article-title":"Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor \u03b1 blockers","volume":"73","author":"Di Minno","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ad.2023.10.019_bib0655","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3945\/ajcn.2008.26427","article-title":"Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial","volume":"88","author":"Gisondi","year":"2008","journal-title":"Am J Clin Nutr."},{"key":"10.1016\/j.ad.2023.10.019_bib0660","doi-asserted-by":"crossref","first-page":"T152","DOI":"10.1016\/j.ad.2021.11.013","article-title":"RF - Role of the Mediterranean Diet in the Treatment of Psoriasis","volume":"114","author":"Berna-Rico","year":"2023","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.ad.2023.10.019_bib0665","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/1203475419874412","article-title":"Weight Loss and Dietary Interventions for Hidradenitis Suppurativa: A Systematic Review","volume":"24","author":"Sivanand","year":"2020","journal-title":"J Cutan Med Surg."},{"key":"10.1016\/j.ad.2023.10.019_bib0670","doi-asserted-by":"crossref","first-page":"676241","DOI":"10.3389\/fmed.2021.676241","article-title":"Features Associated With Quality of Life Impairment in Hidradenitis Suppurativa Patients","volume":"8","author":"Schneider-Burrus","year":"2021","journal-title":"Front Med (Lausanne)."},{"key":"10.1016\/j.ad.2023.10.019_bib0675","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/1535370219900185","article-title":"The immune remodel: Weight loss-mediated inflammatory changes to obesity","volume":"245","author":"Phillips","year":"2020","journal-title":"Exp Biol Med (Maywood)."},{"key":"10.1016\/j.ad.2023.10.019_bib0680","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/nu11010057","article-title":"Role of Nutrition and Adherence to the Mediterranean Diet in the Multidisciplinary Approach of Hidradenitis Suppurativa: Evaluation of Nutritional Status and Its Association with Severity of Disease","volume":"11","author":"Barrea","year":"2018","journal-title":"Nutrients."},{"key":"10.1016\/j.ad.2023.10.019_bib0685","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/oby.2000.8","article-title":"Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group","volume":"8","author":"R\u00f6ssner","year":"2000","journal-title":"Obes Res."},{"key":"10.1016\/j.ad.2023.10.019_bib0690","doi-asserted-by":"crossref","first-page":"721135","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Endocrinol (Lausanne)."},{"key":"10.1016\/j.ad.2023.10.019_bib0695","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/bs.apha.2022.02.005","article-title":"Cardiovascular effects of GLP-1 receptor agonism","volume":"94","author":"Winquist","year":"2022","journal-title":"Adv Pharmacol."},{"key":"10.1016\/j.ad.2023.10.019_bib0700","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.ad.2023.10.019_bib0705","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ad.2023.10.019_bib0710","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1001\/jamacardio.2019.3080","article-title":"Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial","volume":"4","author":"Verma","year":"2019","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.ad.2023.10.019_bib0715","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.2147\/DMSO.S375559","article-title":"The Relationship Between the Blood-Brain-Barrier and the Central Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors","volume":"15","author":"Dong","year":"2022","journal-title":"Diabetes Metab Syndr Obes."},{"key":"10.1016\/j.ad.2023.10.019_bib0720","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jchemneu.2008.07.009","article-title":"Distribution of glucagon-like peptide-1 immunoreactivity in the hypothalamic paraventricular and supraoptic nuclei","volume":"36","author":"Tauchi","year":"2008","journal-title":"J Chem Neuroanat."},{"key":"10.1016\/j.ad.2023.10.019_bib0725","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.2337\/db07-1824","article-title":"Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake","volume":"57","author":"Sandoval","year":"2008","journal-title":"Diabetes."},{"key":"10.1016\/j.ad.2023.10.019_bib0730","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neuroscience.2015.06.054","article-title":"Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease","volume":"303","author":"Liu","year":"2015","journal-title":"Neuroscience."},{"key":"10.1016\/j.ad.2023.10.019_bib0735","doi-asserted-by":"crossref","first-page":"e133429","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight."},{"key":"10.1016\/j.ad.2023.10.019_bib0740","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology."},{"key":"10.1016\/j.ad.2023.10.019_bib0745","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s12325-021-01710-0","article-title":"Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists","volume":"38","author":"Ard","year":"2021","journal-title":"Adv Ther."},{"key":"10.1016\/j.ad.2023.10.019_bib0750","doi-asserted-by":"crossref","first-page":"e13435","DOI":"10.1111\/obr.13435","article-title":"Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials","volume":"23","author":"Iqbal","year":"2022","journal-title":"Obes Rev."},{"key":"10.1016\/j.ad.2023.10.019_bib0755","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/dom.12632","article-title":"Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials","volume":"18","author":"Ard","year":"2016","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.ad.2023.10.019_bib0760","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O\u2019Neil","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.ad.2023.10.019_bib0765","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3390\/jcm12010145","article-title":"Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2022","journal-title":"J Clin Med."},{"key":"10.1016\/j.ad.2023.10.019_bib0770","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/dom.14551","article-title":"Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss","volume":"24","author":"Wharton","year":"2022","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.ad.2023.10.019_bib0775","article-title":"Glucagon-Like Peptide 1 Receptor Agonists in Patients With Inflammatory Arthritis or Psoriasis: A Scoping Review","author":"Karacabeyli","year":"2023","journal-title":"J Clin Rheumatol."},{"key":"10.1016\/j.ad.2023.10.019_bib0780","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ad.2023.10.019_bib0785","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study","volume":"37","author":"Wadden","year":"2013","journal-title":"Int J Obes (Lond)."},{"key":"10.1016\/j.ad.2023.10.019_bib0790","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","article-title":"A Randomized Controlled Trial of Liraglutide for Adolescents with Obesity","volume":"382","author":"Kelly","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ad.2023.10.019_bib0795","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000520217","article-title":"Liraglutide for Weight Management in the Real World: Significant Weight Loss Even if the Maximal Daily Dose Is Not Achieved","volume":"15","author":"Trenson","year":"2022","journal-title":"Obes Facts."},{"key":"10.1016\/j.ad.2023.10.019_bib0800","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1159\/000518325","article-title":"Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland","volume":"14","author":"Haase","year":"2021","journal-title":"Obes Facts."},{"key":"10.1016\/j.ad.2023.10.019_bib0805","doi-asserted-by":"crossref","first-page":"e23780","DOI":"10.1097\/MD.0000000000023780","article-title":"Clinical effectiveness of liraglutide on weight loss in South Koreans: First real-world retrospective data on Saxenda in Asia","volume":"100","author":"Park","year":"2021","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.ad.2023.10.019_bib0810","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/osp4.420","article-title":"Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real-world effectiveness study in Canada","volume":"6","author":"Wharton","year":"2020","journal-title":"Obes Sci Pract."},{"key":"10.1016\/j.ad.2023.10.019_bib0815","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA."},{"key":"10.1016\/j.ad.2023.10.019_bib0820","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ad.2023.10.019_bib0825","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA."},{"key":"10.1016\/j.ad.2023.10.019_bib0830","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0140-6736(21)01640-8","article-title":"Pharmacotherapy for adults with overweight and obesity: A systematic review and network meta-analysis of randomised controlled trials","volume":"399","author":"Shi","year":"2022","journal-title":"Lancet."},{"key":"10.1016\/j.ad.2023.10.019_bib0835","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/j.1468-3083.2012.04609.x","article-title":"Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study","volume":"27","author":"Ahern","year":"2013","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.ad.2023.10.019_bib0840","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/bjd.12886","article-title":"Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal \u03b3\u03b4 T-cell number: a prospective case-series study","volume":"171","author":"Buysschaert","year":"2014","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2023.10.019_bib0845","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1007\/s00125-011-2232-3","article-title":"Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis","volume":"54","author":"Hogan","year":"2011","journal-title":"Diabetologia."},{"key":"10.1016\/j.ad.2023.10.019_bib0850","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/jdv.12629","article-title":"Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients--a randomized placebo-controlled trial","volume":"29","author":"Faurschou","year":"2015","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.ad.2023.10.019_bib0855","first-page":"21-0007","article-title":"Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient","volume":"2021","author":"Costanzo","year":"2021","journal-title":"Endocrinol Diabetes Metab Case Rep."},{"key":"10.1016\/j.ad.2023.10.019_bib0860","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000473873","article-title":"A Disease-Modifying Approach for Advanced Hidradenitis Suppurativa (Regimen with Metformin, Liraglutide, Dapsone, and Finasteride): A Case Report","volume":"9","author":"Khandalavala","year":"2017","journal-title":"Case Rep Dermatol."},{"key":"10.1016\/j.ad.2023.10.019_bib0865","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1111\/dom.14453","article-title":"Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study","volume":"23","author":"Aroda","year":"2021","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.ad.2023.10.019_bib0870","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide Once Weekly for the Treatment of Obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med."}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731023008505?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731023008505?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:17:59Z","timestamp":1757553479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731023008505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":87,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0001731023008505"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2023.10.019","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2023.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2023.06.017","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}